SUPN Supernus Pharmaceuticals Inc.

18.3
+0.98  (+6%)
Previous Close 17.32
Open 17.78
Price To Book 1.62
Market Cap 961,371,706
Shares 52,533,973
Volume 479,357
Short Ratio
Av. Daily Volume 664,138
Stock charts supplied by TradingView

NewsSee all news

  1. Supernus Provides Business Update

    ROCKVILLE, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  2. Supernus to Present at the 2020 Cowen Health Care Conference

    ROCKVILLE, Md., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  3. Supernus Announces Fourth Quarter and Full Year 2019 Financial Results

    Fourth quarter and full year 2019 total revenue of $100.4 million and $392.8 million, respectively.Fourth quarter and full year 2019 net product sales of $97.9 million and $383.4 million, respectively.Fourth quarter and

  4. Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD

    ROCKVILLE, Md., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  5. Supernus to Present at the 2020 J.P. Morgan Healthcare Conference

    ROCKVILLE, Md., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved October 22, 2017.
Oxtellar
Epilepsy
PDUFA date November 8, 2020
SPN-812 (P301)
ADHD
Phase 3 trial did not meet primary endpoint - November 5, 2019.
SPN-810
Impulsive Aggression in ADHD
Approved Aug 19, 2013.
Trokendi
Epilepsy
Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017.
Trokendi
Migraine
FDA approval announced December 14, 2018 to expand label to include monotherapy treatment.
Oxtellar XR
Epilepsy
Phase 3 enrolment put on hold due to COVID-19.
SPN-604
Bipolar depression
Phase 3 trial did not meet primary endpoint - February 25, 2020.
SPN-810 (P302)
Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3 data might be pushed out beyond 2020 due to COVID-19.
SPN-812 (adult)
ADHD

Latest News

  1. Supernus Provides Business Update

    ROCKVILLE, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  2. Supernus to Present at the 2020 Cowen Health Care Conference

    ROCKVILLE, Md., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  3. Supernus Announces Fourth Quarter and Full Year 2019 Financial Results

    Fourth quarter and full year 2019 total revenue of $100.4 million and $392.8 million, respectively.Fourth quarter and full year 2019 net product sales of $97.9 million and $383.4 million, respectively.Fourth quarter and

  4. Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD

    ROCKVILLE, Md., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  5. Supernus to Present at the 2020 J.P. Morgan Healthcare Conference

    ROCKVILLE, Md., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  6. Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients

    ROCKVILLE, Md., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  7. Supernus to Present at Two November Healthcare Conferences

    ROCKVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  8. Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD

    ROCKVILLE, Md., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  9. Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients

    Total revenue of $102.1 million, compared to $103.0 million in third quarter 2018Net product sales of $100.0 million, compared to $100.2 million in third quarter 2018Operating earnings of $39.7 million, compared to $37.5

  10. Supernus to Host Third Quarter 2019 Earnings Conference Call

    ROCKVILLE, Md., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  11. Supernus to Present at the 2019 Cantor Global Healthcare Conference

    ROCKVILLE, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  12. Supernus to Present at Two September Healthcare Conferences

    ROCKVILLE, Md., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system